Machine learning of brain structural biomarkers for Alzheimer's disease (AD) diagnosis, prediction of disease progression, and amyloid beta deposition in the Japanese population

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Japanese Alzheimer's Disease Neuroimaging Initiative¹  Manabu Ishida²  Yoshitomo Shirakashi³  Akihiko Shiino³  Kenji Tanigaki⁴ 

[1] ;Department of Neurology Shimane University Shimane Japan;Molecular Neuroscience Research Center Shiga University of Medical Science Shiga Japan;Research Institute Shiga Medical Center Shiga Japan;

关键词: ADNI;    Alzheimer's disease;    artificial intelligence;    machine learning;    MRI;   

DOI  :  10.1002/dad2.12246

来源: DOAJ

【 摘 要 】

Abstract Introduction We developed machine learning (ML) designed to analyze structural brain magnetic resonance imaging (MRI), and trained it on the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. In this study, we verified its utility in the Japanese population. Methods A total of 535 participants were enrolled from the Japanese ADNI database, including 148 AD, 152 normal, and 235 mild cognitive impairment (MCI). Probability of AD was expressed as AD likelihood scores (ADLS). Results The accuracy of AD diagnosis was 88.0% to 91.2%. The accuracy of predicting the disease progression in non‐dementia participants over a 3‐year observation was 76.0% to 79.3%. More than 90% of the participants with low ADLS did not progress to AD within 3 years. In the amyloid positron emission tomography (PET)–positive MCI, the hazard ratio of progression was 2.39 with low ADLS, and 5.77 with high ADLS. When high ADLS was defined as N+ and Pittsburgh compound B (PiB) PET positivity was defined as A+, the time to disease progression for 50% of MCI participants was 23.7 months in A+N+, whereas it was 52.3 months in A+N‐. Conclusion These results support the feasibility of our ML for the diagnosis of AD and prediction of the disease progression.

【 授权许可】

Unknown